vs
Side-by-side financial comparison of AETHLON MEDICAL INC (AEMD) and Anika Therapeutics, Inc. (ANIK). Click either name above to swap in a different company.
Anika Therapeutics, Inc. is the larger business by last-quarter revenue ($30.6M vs $60.0K, roughly 510.6× AETHLON MEDICAL INC). Anika Therapeutics, Inc. runs the higher net margin — 1.0% vs -2926.4%, a 2927.3% gap on every dollar of revenue. Anika Therapeutics, Inc. produced more free cash flow last quarter ($4.0M vs $-2.0M).
Aethlon Medical Inc. is a clinical-stage medical technology firm that develops targeted therapeutic devices to address life-threatening health conditions. Its lead product, the Hemopurifier, is designed to remove harmful viruses, cancer-derived exosomes, and other pathogens from the bloodstream. The company primarily operates in the infectious disease and oncology healthcare segments, with main market presence in North America.
AEMD vs ANIK — Head-to-Head
Income Statement — Q3 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $60.0K | $30.6M |
| Net Profit | $-1.8M | $292.0K |
| Gross Margin | — | 62.6% |
| Operating Margin | -3026.4% | 2.1% |
| Net Margin | -2926.4% | 1.0% |
| Revenue YoY | — | 0.0% |
| Net Profit YoY | 49.4% | 101.3% |
| EPS (diluted) | $-10.05 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $30.6M | ||
| Q3 25 | — | $27.8M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | — | $26.2M | ||
| Q4 24 | $60.0K | $30.6M | ||
| Q3 24 | $95.1K | $29.6M | ||
| Q2 24 | — | $30.7M | ||
| Q1 24 | — | $29.0M |
| Q4 25 | — | $292.0K | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | — | $-4.0M | ||
| Q1 25 | — | $-4.9M | ||
| Q4 24 | $-1.8M | $-21.9M | ||
| Q3 24 | $-2.8M | $-29.9M | ||
| Q2 24 | — | $-88.0K | ||
| Q1 24 | — | $-4.5M |
| Q4 25 | — | 62.6% | ||
| Q3 25 | — | 56.0% | ||
| Q2 25 | — | 50.9% | ||
| Q1 25 | — | 56.1% | ||
| Q4 24 | — | 56.0% | ||
| Q3 24 | — | 65.7% | ||
| Q2 24 | — | 66.7% | ||
| Q1 24 | — | 65.4% |
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | -11.6% | ||
| Q2 25 | — | -14.8% | ||
| Q1 25 | — | -16.4% | ||
| Q4 24 | -3026.4% | -2.3% | ||
| Q3 24 | -3050.2% | -0.3% | ||
| Q2 24 | — | -5.9% | ||
| Q1 24 | — | -8.6% |
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | -8.4% | ||
| Q2 25 | — | -14.1% | ||
| Q1 25 | — | -18.6% | ||
| Q4 24 | -2926.4% | -71.4% | ||
| Q3 24 | -2950.2% | -101.2% | ||
| Q2 24 | — | -0.3% | ||
| Q1 24 | — | -15.6% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.28 | ||
| Q1 25 | — | $-0.34 | ||
| Q4 24 | $-10.05 | $-1.49 | ||
| Q3 24 | $-16.11 | $-2.03 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.8M | $81.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3M | $143.5M |
| Total Assets | $6.5M | $190.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $81.2M | ||
| Q3 25 | — | $80.2M | ||
| Q2 25 | — | $77.1M | ||
| Q1 25 | — | $75.4M | ||
| Q4 24 | $4.8M | $79.2M | ||
| Q3 24 | $6.9M | $90.7M | ||
| Q2 24 | — | $96.6M | ||
| Q1 24 | — | $100.7M |
| Q4 25 | — | $143.5M | ||
| Q3 25 | — | $146.8M | ||
| Q2 25 | — | $147.7M | ||
| Q1 25 | — | $148.4M | ||
| Q4 24 | $4.3M | $154.0M | ||
| Q3 24 | $6.0M | $179.9M | ||
| Q2 24 | — | $210.3M | ||
| Q1 24 | — | $208.5M |
| Q4 25 | — | $190.3M | ||
| Q3 25 | — | $189.4M | ||
| Q2 25 | — | $187.7M | ||
| Q1 25 | — | $190.6M | ||
| Q4 24 | $6.5M | $202.7M | ||
| Q3 24 | $8.8M | $231.4M | ||
| Q2 24 | — | $262.7M | ||
| Q1 24 | — | $263.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $4.6M |
| Free Cash FlowOCF − Capex | $-2.0M | $4.0M |
| FCF MarginFCF / Revenue | -3357.0% | 13.0% |
| Capex IntensityCapex / Revenue | 3.7% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 15.88× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | — | $-189.0K | ||
| Q1 25 | — | $-130.0K | ||
| Q4 24 | $-2.0M | $1.6M | ||
| Q3 24 | $-2.2M | $5.0M | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | — | $-126.0K |
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $5.0M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-3.0M | ||
| Q4 24 | $-2.0M | $275.0K | ||
| Q3 24 | — | $3.8M | ||
| Q2 24 | — | $-4.5M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | -5.9% | ||
| Q1 25 | — | -11.3% | ||
| Q4 24 | -3357.0% | 0.9% | ||
| Q3 24 | — | 12.9% | ||
| Q2 24 | — | -14.6% | ||
| Q1 24 | — | -6.7% |
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | 3.7% | 4.3% | ||
| Q3 24 | 0.0% | 4.1% | ||
| Q2 24 | — | 11.1% | ||
| Q1 24 | — | 6.2% |
| Q4 25 | — | 15.88× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AEMD
Segment breakdown not available.
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
